<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964336</url>
  </required_header>
  <id_info>
    <org_study_id>314376 - FORSKER20</org_study_id>
    <nct_id>NCT04964336</nct_id>
  </id_info>
  <brief_title>An Observational Study to Investigate the Role of B Cells in Multiple Sclerosis</brief_title>
  <official_title>Decoding the B Cell Response in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) typically afflict young people in their twenties, when they start a&#xD;
      career and establish a family. The disease thus imposes a severe impact on quality of life&#xD;
      and heavy economic burdens on society. Critical barriers to progress in the field are the&#xD;
      lack of knowledge of relevant immune cell subsets driving the pathology and the targets of&#xD;
      the immune response within the central nervous system. In this project, we will test the&#xD;
      hypothesis that a subgroup of MS patients is defined by a genetically determined B cell&#xD;
      response against specific antigenic epitopes. The hypothesis is based on our recent,&#xD;
      pioneering results showing that approximately half of MS patients have a restricted&#xD;
      population of B cells in the cerebrospinal fluid defined by polymorphisms in the constant&#xD;
      heavy-chain of the immunoglobulin B cell receptor, the G1m1 allotype. Here, we aim to&#xD;
      characterize the G1m1 B cells, to disentangle the genetic basis of the B cell response, and&#xD;
      to identify the molecular targets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The transcriptome of B cells from blood and cerebrospinal fluid</measure>
    <time_frame>1 day (subject inclusion)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The immunglobulin receptors of B cells from blood and cerebrospinal fluid</measure>
    <time_frame>1 day (subject inclusion)</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Multiple sclerosis</arm_group_label>
    <description>Patients with relapsing-remitting multiple sclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis of B cells</intervention_name>
    <description>B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq</description>
    <arm_group_label>Multiple sclerosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and cerebrospinal fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under diagnostic work-up for multiple sclerosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms and brain MRI scans strongly suggestive of multiple sclerosis according to&#xD;
             the 2017 McDonald revisions&#xD;
&#xD;
          -  Intrathecal immunoglobulin G synthesis&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with immunomodulatory drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Lossius</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Lossius, MD, PhD</last_name>
    <phone>+47 93068515</phone>
    <email>postmottak@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trygve Holmøy, MD, PhD</last_name>
      <phone>+4767960000</phone>
      <email>postmottak@ahus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pål Berg-Hansen</last_name>
      <phone>+47 22118080</phone>
      <email>post@oslo-universitetssykehus.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Andreas Lossius</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

